# Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin

> **NCT07124819** · PHASE3 · COMPLETED · sponsor: **Avexima Diol LLC** · enrollment: 215 (actual)

## Conditions studied

- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
- Venous Thromboembolism (VTE)
- Prevention

## Interventions

- **DRUG:** Sodium enoxaparin
- **DRUG:** Dimolegin
- **DRUG:** Dimolegin placebo
- **DRUG:** Sodium enoxaparine placebo

## Key facts

- **NCT ID:** NCT07124819
- **Lead sponsor:** Avexima Diol LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-22
- **Primary completion:** 2025-01-14
- **Final completion:** 2025-01-14
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07124819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07124819, "Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07124819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*